Dr Doshi and colleagues used the study sample to predict what costs would have been using the MedPAC proposals and found that for patients using specialty RA drugs, the OOP costs would remain front loaded into the beginning of the year, ranging from $512 to $1076 per month from January to May.
The researchers observed that previous studies of dermatologic diseases have shown a much higher prevalence of depression in patients with CLE—in some cases double or triple that of the general population.
Read Now
Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.